Posted by Michael Wonder on 11 Jun 2020
Rare disease therapy development and access remain top FDA priorities during COVID-19
11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these patients are among the most vulnerable to COVID-19, either directly or indirectly.
Many rare disease patients also depend on reliable access to high quality, life-saving medications.
While COVID-19 is a major public health priority, the FDA’s work to advance treatments for rare diseases and helping ensure continuity of care for people with rare diseases remain top priorities.
